Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP).

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Nephrology, Dialysis and Transplantation

• Publication date

  2008-11-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ndt/gfn653PMID 19037082
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin δ

  2008cited by this paper
• Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.

  2008cited by this paper
• European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP).

  2008cited by this paper
• Are the synergistic effects of high-volume haemofiltration and enhanced adsorption the missing key in sepsis modulation?

  2008cited by this paper
• Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study

  2008cited by this paper
• C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.

  2008cited by this paper
• Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death.

  2008cited by this paper
• Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

  2008influential reference
• The normal hematocrit study--follow-up.

  2008cited by this paper
• Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.

  2007cited by this paper
• Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

  2007cited by this paper
• C.E.R.A. Maintains Stable Control of Hemoglobin in Patients with Chronic Kidney Disease on Dialysis when Administered Once Every Two Weeks

  2007cited by this paper
• The first human cell line-derived erythropoietin, epoetin-delta (Dynepo), in the management of anemia in patients with chronic kidney disease.

  2007cited by this paper
• Hemoglobin variability and mortality in ESRD.

  2007cited by this paper
• Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration*

  2007cited by this paper
• Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).

  2007cited by this paper
• Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.

  2007cited by this paper
• Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.

  2007cited by this paper
• Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients

  2007cited by this paper
• Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.

  2007cited by this paper
• Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.

  2007cited by this paper
• The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.

  2007cited by this paper
• Comparative Erythropoietin Receptor Binding Kinetics of C.E.R.A. and Epoetin-β Determined by Surface Plasmon Resonance and Competition Binding Assay

  2007cited by this paper
• KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target.

  2007cited by this paper
• KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target.

  2007cited by this paper
• Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.

  2007cited by this paper
• Epoetin delta is effective for the management of anaemia associated with chronic kidney disease*

  2006cited by this paper
• Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

  2006influential reference
• KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.

  2006cited by this paper
• II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults.

  2006cited by this paper
• Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.

  2006cited by this paper
• KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.

  2006cited by this paper
• Correction of anemia with epoetin alfa in chronic kidney disease.

  2006influential reference
• Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple‐dose, phase II study

  2006cited by this paper
• Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia.

  2006cited by this paper
• Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

  2005cited by this paper
• Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.

  2005cited by this paper
• Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.

  2005cited by this paper
• Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials.

  2004cited by this paper
• Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.

  2004cited by this paper
• The burden of kidney disease: improving global outcomes.

  2004influential reference
• Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.

  2004cited by this paper
• Micelle-Associated Protein in Epoetin Formulations: A Risk Factor for Immunogenicity?

  2003cited by this paper
• Hemoglobin variability in epoetin-treated hemodialysis patients.

  2003cited by this paper
• Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.

  2002cited by this paper
• THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN

  2000cited by this paper
• European best practice guidelines for the management of anaemia in patients with chronic renal failure.

  1999influential reference
• The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

  1998cited by this paper

• Efficacy and safety of high-dose intravenous iron in the treatment of iron-deficiency anemia in patients undergoing hemodialysis: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Algorithm-managed dosing and pharmacist-managed dosing of erythropoietin stimulating agents in renal anaemia: a systematic review

  2025cites this paper
• Comprehensive Characterization of Hematological, Renal, and Cardiovascular Profiles in Chronic Kidney Disease Patients With Pulmonary Hypertension

  2025cites this paper
• Evidence of pancreatic iron deposits and their association with mortality in dialysis-associated iatrogenic hemosiderosis

  2025cites this paper
• Prevalence and Determinants of Anaemia during Pregnancy in the Central Region of Burkina Faso: Case of the Malaria Peak and Harvesting Period

  2025cites this paper
• Bridging the Gap Between CKD Management Paradigms in Transplant and Nontransplant Settings: Published Evidence, Challenges, and Perspectives

  2024cites this paper
• Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease

  2024cites this paper
• Management of anaemia and prognosis of patients undergoing maintenance peritoneal dialysis: A nationwide cohort study

  2024cites this paper
• The Efficacy and Safety of Roxadustat for Anemia in Hemodialysis Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials

  2024influential citation
• Exploring The Prevalence And Underlying Causes Of Anemia In Hemodialysis Patients. A Cross-Sectional Study

  2024cites this paper
• Options for correcting nephrogenic anemia in a patient with HIV and chronic kidney disease. Case report

  2024cites this paper
• Anemia in Pregnancy With CKD

  2024cites this paper
• Relationship Between the Effect of Roxadustat and Comorbid Diabetes in Non-dialyzed Chronic Kidney Disease Patients: A Retrospective Observational Study

  2023cites this paper
• Epidemiology and treatment of renal anaemia in Spain: RIKAS retrospective study.

  2023cites this paper
• Anemia combined with albuminuria increases the risk of cardiovascular and renal events, regardless of a reduced glomerular filtration rate, in patients with type 2 diabetes: a prospective observational study

  2023cites this paper
• ESKD: Peritoneal Dialysis

  2023cites this paper
• Ferroptotic mechanisms and therapeutic targeting of iron metabolism and lipid peroxidation in the kidney

  2023cites this paper
• Treatment Options for Anemia in Kidney Transplant Patients: A Review

  2023cites this paper
• Relation of Liver Siderosis to Liver Fibrosis in Hemodialysis Patients with Severe Hyperferritinemia Secondary to High Doses of Intravenous Iron Supplementation.

  2022cites this paper
• Erythropoietin Resistance Development in Hemodialysis Patients: The Role of Oxidative Stress

  2022cites this paper
• Prognostic Value of the Malnutrition-inflammation Score in Hospitalization and Mortality on Long-term Hemodialysis.

  2021cites this paper
• Hemodialysis Centers Guide 2020

  2021cites this paper
• Guía de unidades de hemodiálisis 2020

  2021cites this paper
• A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps

  2021cites this paper
• Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial

  2021cites this paper
• Comparative effectiveness of erythropoietin alpha and beta in hemodialysis patients: a single-center prospective observational study

  2021cites this paper
• Preoperative Therapy for Anemia

  2021cites this paper
• Perioperative management of patients with renal failure

  2021cites this paper
• Influence of Pretransplant Factors on Posttransplant Anemia Recovery Rate in Primary Deceased Donor Kidney Transplant Recipients.

  2021cites this paper
• Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents

  2021cites this paper
• Efficacy of single and multiple doses of fenbendazole against gill parasites ( Dactylogyrus sp.) of Labeo rohita (Hamilton, 1822) and its physio‐metabolic effects on the fish

  2020cites this paper
• Mixed hemodiafiltration reduces erythropoiesis stimulating agents requirement in dialysis patients: a prospective randomized study

  2020cites this paper
• CERA conversion to darbepoetin alfa in 154 hemodialysis patients

  2020cites this paper
• ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE

  2020cites this paper
• Haematological disorders following kidney transplantation.

  2020cites this paper
• Identifying Biomarker Profiles Through the Epidemiologic Analysis of Big Health Care Data – Implications for Clinical Management and Clinical Trial Design

  2020cites this paper
• A pharmacist‐managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial

  2020cites this paper
• Systematic review of guidelines for the diagnosis and treatment of iron deficiency anemia using intravenous iron across multiple indications

  2020cites this paper
• Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis

  2020cites this paper
• ERKRANKUNGEN DER NIERE

  2020cites this paper
• Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach

  2019cites this paper
• Effectiveness and safety of ferric carboxymaltose therapy in peritoneal dialysis patients: an observational study

  2019cites this paper
• Parenteral versus oral iron therapy for adults and children with chronic kidney disease.

  2019cites this paper
• Caskey, F. (2017). Attainment of guideline targets in EURODOPPS haemodialysis patients: are differences related to a country’s healthcare expenditure and nephrologist workforce? Nephrology Dialysis Transplantation , 32 (10).

  2019cites this paper
• Gender Differences in Dose of Erythropoietin to Maintain Hemoglobin Target in Hemodialysis Patients

  2019cites this paper
• "Doctor, can I have less frequent injection with highly efficient treatment?" A patient centered study using an electronic choice-based conjoint analysis (ePRO) to assess real world preferences regarding erythropoiesis stimulating agent to treat anaemia in chronic kidney disease (PERCEPOLIS study).

  2019cites this paper
• Hepatic iron load differs strikingly between peritoneal dialysis and hemodialysis patients

  2019influential citation
• Guideline attainment and morbidity/mortality rates in a large cohort of European haemodialysis patients (EURODOPPS).

  2019cites this paper
• Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations

  2019cites this paper
• Clinical practice guidelines for the provision of renal service in Hong Kong: Peritoneal Dialysis

  2019cites this paper
• Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies

  2019cites this paper
• Intravenous Iron and Maintenance Hemodialysis.

  2019cites this paper
• Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies

  2019cites this paper
• Estudio de la ferropenia en el laboratorio clínico

  2019cites this paper
• Assessment of iron-restricted erythropoiesis in chronic renal disease: evaluation of Abbott CELL-DYN Sapphire mean reticulocyte hemoglobin content (MCHr)

  2019cites this paper
• Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study

  2018cites this paper
• ADDIS ABABA UNIVERSITY COLLEGE OF HEALTH SCIENCES DEPARTMENT OF MEDICAL BIOCHEMISTRY ASSESSMENT OF SERUM ELECTROLYTE LEVEL AND KIDNEY FUNCTION TESTS AMONG ETHIOPIAN PUBLIC HEALTH INSTITUTE STAFF MEMBERS: A CROSS SECTIONAL STUDY. BY MESERET DERBEW (BSc)

  2018cites this paper
• University of Groningen Posttransplant Anemia as a Prognostic Factor of Mortality in Kidney-Transplant Recipients

  2018cites this paper
• Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease

  2018cites this paper
• When should iron supplementation in dialysis patients be avoided, minimized or withdrawn?

  2018cites this paper
• Периоперационное ведение пациентов с почечной недостаточностью

  2018cites this paper
• Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.

  2017cites this paper
• Posttransplant Anemia as a Prognostic Factor of Mortality in Kidney-Transplant Recipients

  2017cites this paper
• Impact of iatrogenic iron overload on the course of hepatitis C in the dialysis population: A plea for caution

  2017cites this paper
• Reticulocyte Hemoglobin Content Helps Avoid Iron Overload in Hemodialysis Patients: A Retrospective Observational Study.

  2017cites this paper
• Early winners and losers in dialysis center pay-for-performance

  2017cites this paper
• Quality of sleep in hemodialysis patients: The role of demographic and clinical characteristics

  2017cites this paper
• Attainment of guideline targets in EURODOPPS haemodialysis patients: are differences related to a country’s healthcare expenditure and nephrologist workforce?

  2017cites this paper
• Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study

  2017cites this paper
• Iatrogenic iron overload and its potential consequences in patients on hemodialysis.

  2017cites this paper
• Technology Medicine Open Access book

  2017influential citation
• Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients.

  2017cites this paper
• Evaluation of the Impact of a New Synthetic Vitamin E-Bonded Membrane on the Hypo-Responsiveness to the Erythropoietin Therapy in Hemodialysis Patients: A Multicenter Study

  2017cites this paper
• Effect of Erythropoietin Stimulating Agents on Cardiovascular Events in Chronic Kidney Disease Patients on Hemodialysis

  2017cites this paper
• Suministro semanal de Eritropoyetina Humana Recombinante alfa en pacientes incidentes de diálisis peritoneal. Seguimiento de 12 meses

  2017cites this paper
• Hematocrit and mortality in hemodialysis patients: A registry analysis from the KiHeart Cohort

  2017cites this paper
• [Iron deficiency : Recognition and treatment].

  2017cites this paper
• Hepatic Iron Load at Magnetic Resonance Imaging Is Normal in Most Patients Receiving Peritoneal Dialysis

  2017cites this paper
• A novel complex model of hemodialysis adequacy: predictive value and relationship with malnutrition-inflammation score

  2017influential citation
• Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study

  2017cites this paper
• A threshold trajectory was revealed by isolating the effects of hemoglobin rate of rise in anemia of chronic kidney disease

  2017cites this paper
• Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century

  2016cites this paper
• Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study

  2016cites this paper
• The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease

  2016cites this paper
• International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study.

  2016cites this paper
• Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials

  2016cites this paper
• Continuous Erythropoietin Receptor Activator (C.E.R.A.) Treatment of Renal Anemia in Patients with Chronic Kidney Disease: A Two-Year Observational Study

  2016cites this paper
• Characteristics, Cardiovascular Comorbidity and Medicines Management in Patients with Type 2 Diabetes and CKD: Results of the IRIDIEM Study

  2016cites this paper
• [The role of renal anemia and cardiovascular disease in the progression of chronic glomerulonephritis].

  2016cites this paper
• Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013.

  2016cites this paper
• Hemoglobin Outcomes during Administration of Continuous Erythropoietin Receptor Activator (C.E.R.A): A Prospective, Observational,

  2015cites this paper
• Reassessment of Iron Biomarkers for Prediction of Dialysis Iron Overload: An MRI Study

  2015cites this paper
• Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study)

  2015cites this paper
• Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review.

  2015cites this paper
• Administration of iron in renal anemia.

  2015cites this paper
• UK Renal Registry 17th Annual Report: Chapter 7 Haemoglobin, Ferritin and Erythropoietin amongst UK Adult Dialysis Patients in 2013: National and Centre-specific Analyses

  2015cites this paper
• Early versus delayed erythropoietin for the anaemia of end-stage kidney disease.

  2015cites this paper
• Primena gvođa u lečenju anemije bubrenog porekla

  2015cites this paper
• Management of Anemia in Chronic Kidney Disease

  2015cites this paper
• UK Renal Registry 17th Annual Report: Chapter 7 Haemoglobin, Ferritin and Erythropoietin amongst UK Adult Dialysis Patients in 2013: National and Centre-specific Analyses

  2015cites this paper